Emily S Weyburne
Structure-Based Design of Inhibitors Selective for Human Proteasome β2c or β2i Subunits
Xin B, Groll M, van der Marel G, Driessen C, Florea B, Kisselev A, Weyburne E, Janssens M, Du Y, Espinal C, Maurits E, Heinemeyer W, de Bruin G, Huber E, Overkleeft H. Structure-Based Design of Inhibitors Selective for Human Proteasome β2c or β2i Subunits. J Med Chem 2019; 62:1626-1642.
05.02.2019Structure-Based Design of Inhibitors Selective for Human Proteasome β2c or β2i Subunits
05.02.2019J Med Chem 2019; 62:1626-1642
Xin Bo-Tao, Groll Michael, van der Marel Gijsbert A, Driessen Christoph, Florea Bogdan I, Kisselev Alexei F, Weyburne Emily S, Janssens Marissa, Du Yimeng, Espinal Christofer, Maurits Elmer, Heinemeyer Wolfgang, de Bruin Gerjan, Huber Eva M, Overkleeft Herman S
The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells
Kraus M, Overkleeft H, Kisselev A, Li N, Appenzeller C, van Rooden E, Haile S, de Bruin G, van der Linden W, Shabaneh T, Silzle T, Mirabella A, Weyburne E, Geurink P, Bader J, Driessen C. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells. Haematologica 2015; 100:1350-60.
11.06.2015The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells
11.06.2015Haematologica 2015; 100:1350-60
Kraus Marianne, Overkleeft Herman, Kisselev Alexei F, Li Nan, Appenzeller Christina, van Rooden Eva, Haile Sarah, de Bruin Gerjan, van der Linden Wouter A, Shabaneh Tamer B, Silzle Tobias, Mirabella Anne C, Weyburne Emily S, Geurink Paul P, Bader Juergen, Driessen Christoph